Pharvaris N.V. PHVS

$31.68 +0.56 (1.80%)

Valuation

Market cap
1,994,290,000
Revenue TTM
$0
Net income TTM
$-198,790,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
341,800
Avg volume
819,262
Day's range
$30.58 – $32.32
Shares out
65,408,000
Stochastic %K
26%
Beta
-2.46
Analysts
Strong Sell
Price target
$59.85

Price

Company profile

Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema du...

Show more

Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.

Industry
Biotechnology
Sector
Healthcare
Phone
31 712036410
Website
https://pharvaris.com
Address
Grafenauweg 8, Zug, Switzerland

Latest news

Stocktwits

Quantumup Oct 6, 11:43 AM
H.C. Wainwright reit'd $PHVS Buy-$60 after recently hosting Pharvaris mgmt at its 28th Annual Global Investment Conference and have since conducted a deep-dive analysis of the upcoming catalysts for deucrictibant. $TAK $BCRX CSLLY IONS Here's what H.C. Wainwright said in its note: https://x.com/Quantumup1/status/2107436482214425028?s=20
1 replies
Merlintrader Oct 4, 11:59 PM
Pharvaris ($PHVS): Can Positive HAE Data Become Two Launches? Explore the company, catalysts and risks in our research hub. https://www.merlintrader.com/pharvaris-stock-hub/
0 replies
De_Monitor Sep 30, 4:58 PM
$PHVS $PHAR My prediction: Pharvaris gets acquired. With approval expected within the next few months and a potentially very valuable oral HAE franchise approaching commercialization, I think the window for a takeover is opening fast. A larger pharma could prefer to acquire Pharvaris before approval or shortly after, rather than wait until the full commercial value of the franchise becomes visible. Wouldn’t surprise me at all if Pharvaris gets bought out around approval. 💰🚀
0 replies
CH_Expat Sep 29, 1:43 PM
$PHVS Interested at 1.5b to 1.7b MC. Expect the slow bleed to continue.
0 replies
cubie Sep 26, 6:04 PM
$PHVS $VERA $KOD $TRVI oh sorry u got everything Wrong since then.🤭😆 so broken clock comment is twice a year u get one bio right out 10😂🤣. so again how does a tard get 9 out 10 spec bios wrong??? a 5 dog can guess with a higher success rate then u noobtard
0 replies
cubie Sep 26, 6:02 PM
$TRVI "most bullish triangle in bio land" this tard said. 😂🤣, again how does one only post on spec bios $VERS $PHVS $KOD and manage to get them all wrong????🤔🤣. even a broken clock is right twice a day. u wrong for 2 months lmao😂🙄
1 replies
CH_Expat Sep 26, 6:00 PM
$PHVS $VERA $KOD Was expecting that, therefore a small screenshot for the audience where Death Cab for Cubie praised me. So blocking as usual will not help her this time. She is quite dumb.
2 replies
cubie Sep 26, 5:57 PM
$PHVS $VERA $KOD ok when this tard, who dont know sht and says any spec bio is "derisked", u sell and/ short. cubie teaches how to make money from these useless tards🫡😁
0 replies